CANOGA PARK, Calif., May 16, 2017 /PRNewswire/ -- One Lambda, a Thermo Fisher Scientific brand, announced today that it has signed an exclusive licensing agreement with Transcriptome Sciences Inc. (TSI) of Edmonton, Canada for its new microarray biopsy service, the Molecular Microscope™ Diagnostic System (MMDx).
Developed by TSI, MMDx is a central diagnostic system that uses a "MyGeneChip™ Custom Microarray from Thermo Fisher Scientific to measure transcript levels in biopsies, apply algorithms and compare algorithm results to a set of reference biopsies. The system was developed for kidney transplant biopsies by Dr. Phil Halloran in the Alberta Transplant Applied Genomics Centre at the University of Alberta in Edmonton, Canada, and its company, Transcriptome Sciences Inc. (TSI). The Molecular Microscope system has been adapted to read heart transplant biopsies and is now being adapted to read lung and liver transplant biopsies. The mission is to change the care of patients in organ transplantation with this new central diagnostic system.
"The MMDx is a truly innovative way of assessing transplant rejection. There is a lot of contention with the results from the current technology," said Dr. Jon Kobashigawa, Cardiologist and Director of the Heart Transplant Program at Cedars-Sinai Hospital in Los Angeles.
The MMDx system complements conventional biopsy processing to improve the assessment of rejection and injury in transplanted organs. In addition, it can provide theranostics support for drug development and use. Kashi Clinical Laboratories, Inc., a CLIA licensed CAP accredited laboratory located in Portland, Oregon, has recently adopted this technology. This Laboratory Based Service will be offered by Kashi in collaboration with TSI for processing of sample biopsies in the US. Kashi Clinical Laboratories is licensed in all states, including New York, California and Florida. Visit www.molecular-microscope.com for more information on the MMDX tests provided by Kashi Laboratories.
About One Lambda
One Lambda, a Thermo Fisher Scientific Brand, is the worldwide leader in HLA typing and antibody detection assays. Known for its commitment to quality, service, and innovation, the company develops and distributes several lines of HLA typing and antibody detection tests utilizing serological, molecular, ELISA, Flow, Luminex xMAP, & NGS technologies. In addition, One Lambda also manufactures laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations. For more information, please visit www.onelambda.com
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thermo-fisher-scientifics-one-lambda-brand-signs-exclusive-licensing-agreement-with-transcriptome-sciences-inc-for-access-to-molecular-microscope-diagnostic-system-300458149.html
SOURCE Thermo Fisher Scientific Inc.